Skip to main content
Fig. 1 | BMC Nephrology

Fig. 1

From: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure

Fig. 1

Study schedule. The study schedule was divided into three phases – Titration (12 weeks) which, included a 4-week baseline period at the end, Maintenance (28 weeks) which, included a 4-week evaluation period at the end and an open-label extension phase (24 weeks). Subjects were randomised at the end of the Titration phase

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us